Juvenile Huntington Disease:CT and MR Features
AJNR 16:1405-1412, Ho,V.B.,et al, 1995
Serial Changes of Cerebral Glucose Metab & Caudate Size in Persons at Risk for Huntington's Dis
Arch Neurol 49:1161-1167, Grafton,S.T.,et al, 1992
Clinical-Pathologic Correlation in Huntington's Disease:A Neuropsychological and Computed Tomography Study
Neurol 39:796-801, Bamford,K.A.,et al, 1989
Normal Caudate Glucose Metabolism in Persons at Risk for Huntington's Disease
Arch Neurol 44:254-257, Young,A.B.,et al, 1987
Reduced Cerebral Glucose Metabolism in Asymptomatic Subjects at Risk for Huntington's Disease
NEJM 316:357-362, Mazziotta,J.C.,et al, 1987
The Combined Use of Positron Emission Tomography & DNA Polymorphisms for Preclinical Detection of Huntington's Disease
Neurol 37:1441-1447, Hayden,M.R.,et al, 1987
Positron Emission Tomography in the Early Diagnosis of Huntington's Disease
Neurol 36:888-894, Hayden,M.R.,et al, 1986
Positron Computed Tomography for Studies of Myocardial & Cerebral Function
Ann Int Med 98:339-359, Phelps,M.E.,et al, 1983
Computerized Axial Tomography-Use in the Dx. of Dementia
JAMA 234:754, Menzer,L.,et al, 1975
Complete Evaluation of Dementia: PET and MRI Correlation and Diagnosis for the Neuroradiologist
AJNR 42:998-1007, Oldan, J.D.,et al, 2021
PET Scan Investigations of Huntington's Disease:Cerebral Metabolic Corr. of Neuro & Funct Decline
Ann Neurol 20:296-303, Young,A.B.,et al, 1986
Bicaudate Index in Computerized Tomography of Huntington Disease & Cerebral atrophy
Neurol 28:1196-1200, Barr,A.N.,et al, 1978
Huntington Disease: Clinical Features and Diagnosis
UptoDate Dec 2017, Oksana Suchowersky, 2017
Evidence-Based Guideline: Pharmacologic Treatment of Chorea in Huntington Disease
Neurol 79:597-603, Armstrong, M.J. & Miyasaki, J.M., 2012
Huntingtons Disease
BMJ 341:34-40, Novak,M.J. &Tabrizi,S.J., 2010
Predictors of Diagnosis in Huntington Disease
Neurol 68:1710-1717, Langbehn,D.R.,et al, 2007
Neural Transplantation in Huntington Disease: Long-Term Grafts in Two Patients
Neurol 68:2093-2098, Keene,C.D.,et al, 2007
Psychiatric Disorders in Preclinical Huntingtons Disease
JNNP 78:939-943, Julien,C.L.,et al, 2007
Tetrabenazine as Antichorea Therapy in Huntington Disease, A Randomized Controlled Trial
Neurol 66:366-372, Huntington Study Group, 2006
The Association of CAG Repeat Length with Clinical Progression in Huntington Disease
Neurol 66:1016-1020, Rosenblatt,A.,et al, 2006
Saccades in Presymptomatic and Early Stages of Huntington Disease
Neurol 67:394-399, Blekher,T.,et al, 2006
Identification of an Oculomotor biomarker of Preclinical Huntington Disease
Neurol 67:485-487, Golding,C.V.P.,et al, 2006
Effect of Donepezil on Motor and Cognitive Function in Huntington Disease
Neurol 67:1268-1271, Cubo,E.,et al, 2006
Functional Brain Changes in Presymptomatic Hunington's Disease
Ann Neurol 55:879-883, Reading,S.A.,et al, 2004
Prenatal Diagnosis Requests for Huntington's Disease when the Father is at Risk, and Does Not Want to Know His Genetic Status: Clinical, Legal, and Ethical Viewpoints
BMJ 326:331-333, Tassicker,R.,et al, 2003
Intoxication with Riluzole in Huntington's Diease
Neurol 57:1141-1143, Bodner,Th.,et al, 2001
Family History and DNA Analysis in Patients With Suspected Huntington's Disease
JNNP 69:54-59, Siesling,S. et al, 2000
Predictive Testing for Huntington's Disease: the Calm After the Storm
Lancet 356:1944-1945, Hayden,M.R., 2000
Motor and Cognitive Improvements in Patients with Huntington's Disease after Neurol Trasnplantation
Lancet 356:1975-1979,1945, Bachoud-Levi,A.,et al, 2000
Molecular Basis of the Neurodegenerative Disorders
NEJM 340:1970-1980, Martin,J.B., 1999
iH NMR Spectroscopy Studies of Huntington's Disease, Correlations with CAG Repeat Numbers
Neurol 50:1357-1365, Jenkins,B.G.,et al, 1998
Patients with Features Similar to Huntington's Disease, Without CAG Expansion in Huntingtin
Neurol 51:215-220, Rosenblatt,A.,et al, 1998
Few Psychological Consequences of Presymptomatic Testing for Huntington Disease
Lancet 349:4, Bundey,S., 1997
Longitudinal Change in Basal Ganglia Volume in Patients with Huntington's Disease
Neurol 48:394-399, Aylward,E.H.,et al, 1997
CAG Repeat Number Governs the Development Rate of Pathology in Huntington's Disease
Ann Neurol 41:689-692, Penney,J.B.,et al, 1997
Genetic Testing of Children at Risk for Huntington's Disease
Neurol 49:1048-1053, Nance,M.A.,et al, 1997
Relationship Between Trinucleotide Repeats and Neuropathological Changes in Huntington's Disease
Ann Neurol 39:132-136, Furtado,S.,et al, 1996
Assessment of Brain SPECT:Report of the Therapeutics and Technology Assessment Subcommittee of the AAN
Neurol 46:278-285, , 1996
Trinucleotide Repeat Length and Clinical Progression in Huntington's Disease
Neurol 46:527-531, Brandt,J.,et al, 1996
Psychiatric Symptoms Do Not Correlate with Cognitive Decline, Motor Sympt or CAG Repeat Length in Huntington's
Arch Neurol 53:493-497, Zappacosta,B.,et al, 1996
Motor Changes in Presymptomatic Huntington Disease Gene Carriers
Arch Neurol 53:487-492, Siemers,E.,et al, 1996
Diagnosis of Patients Presenting to a Huntington Disease (HD) Clinic without a Family History of HD
Neurol 47:1578-1580, Nance,M.A.,et al, 1996
Hereditary Late-Onset Chorea Without Significant Dementia:Genetic Evid for Phenotypic Variation in Huntington's Disease
Neurol 45:443-447, Britton,J.W.,et al, 1995
Correlations Between Triplet Repeat Expansion and Clinical Features in Huntington's Disease
Arch Neurol 113:749-753, Claes,S.,et al, 1995
The Prevention of Neurogenetic Disease
Arch Neurol 52:356-362, 3451995., Rosenberg,R.N.&Iannaccone,S.T., 1995
The Neurogenetic Genie:Testing for Huntington's Disease Mutation
Neurol 44:1369-1373, 1533-15361994., Hersch,S.,et al, 1994
CAG Repeat Size and Clinical Presentation in Huntington's Disease
Neurol 44:1137-1143, Ashizawa,T.,et al, 1994
A Worldwide Study of the Huntington's Disease Mutation, The Sensitivity & Specificity of Measuring CAG Repeats
NEJM 330:1401-1406, 14501994., Kremer,B.,et al, 1994
Clozapine in Huntington's Chorea
Neurol 44:821-823, Bonuccelli,U.,et al, 1994